J. Solera, P. Geijo and J. Largo, “Arandomized, Double-Blind Study to Assess the Optimal Duration of Doxycycline Treatment for Human Brucellosis,” Clinical Infectious Diseases, Vol. 39, No. 12, 2004, pp. 1776-1782. doi:10.1086/426024

has been cited by the following article:

• TITLE: The Assessment of the Clinical Effect of the Drug Compatibility and Course of Treatment to the Brucellar Spondylitis

  AUTHORS: Xin-Ming Yang, Wei Shi, Xian-Yong Meng, Ying Zhang, Ya-Kun Du, Lei Zhang, Yao-Yi Wang

  KEYWORDS: Brucellosis; Spondylitis; Clinic Effect; Course of Treatment; Drug Compatibility

  JOURNAL NAME: Surgical Science, Vol.4 No.1, January 29, 2013

  ABSTRACT: Objective: To evaluate five drug treatment regimens in the treatment of Brucella spondylitis. Methods: Patients with clinical symptoms compatible and diagnostic test consistent with Brucella spondylitis were randomly assigned to five drug treatment regimens. Results: Combination therapy with doxycycline, rifampin and sulfamethoxazole for 56 consecutive days showed the highest cure rate of 20% after a single course and of 85% after a double course with affectivity rates of 55% and 95%. Cure rate and affectivity rate was significant better (P 0.05) than for patients receiving doxycycline, rifampin and streptomycin for the same period and regimens containing doxycycline were significant better than regimens without this drug. Conclusion: Combination therapy of doxycycline, rifampin and sulfamethoxazole for 8 weeks using one or two full courses should be recommended for Brucella spondylitis.